Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
110results about How to "Prevent and treat disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
InactiveUS20080014194A1Improves motor characteristicInhibit deteriorationNervous disorderImmunoglobulins against animals/humansTherapeutic treatmentAmyloid
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1
Glp-1 and methods for treating diabetes
InactiveUS20090088369A1Reduce the amount requiredPrevent and treat diseasePeptide/protein ingredientsMetabolism disorderDiabetes mellitusTreatment level
The present invention relates to use of GLP-1 or a related molecule having a GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday.” Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.
Owner:ZEALAND PHARM AS
Prevention and treatment of amyloidogenic disease
InactiveUS20050123544A1Prevent and treat diseaseImmunoglobulins against animals/humansAntibody ingredientsTherapeutic treatmentImmunogenicity
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY
Modified free-living microbes, vaccine compositions and methods of use thereof
InactiveUS20080248066A1Reduce microbesReduce spreadBacterial antigen ingredientsBacteriaHeterologous AntigensMicroorganism
Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and / or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and / or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and / or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Beta-amyloid protein production/secretion inhibitors
InactiveUS6586475B1Strong inhibitory activityPrevent and treat diseaseBiocideOrganic active ingredientsNitrogen atomAmyloid
A compound of the formula:wherein Ar is an aromatic group; X and Y are a bivalent group selected from -O-, -S-, -CO-, -SO2-, -NR8-, -CONR8-, SO2NR8 and -COO- (wherein R8 is H, a hydrocarbon group or acyl), or a bivalent C1-6 aliphatic hydrocarbon group which may contain one or two above bivalent groups; R1 and R2 are H or C1-6 alkyl, or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring; and ring A is a monocyclic aromatic ring, or a salt thereof or a prodrug thereof exhibits an excellent inhibitory activity of the production and / or the secretion of amyloid-beta protein.
Owner:TAKEDA PHARMACEUTICA CO LTD
Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
To provide a diagnostic drug which binds specifically to an amyloid aggregate and / or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and / or deposition.The invention provides a compound represented by formula (1):(wherein X1 represents an optionally substituted bicyclic heterocyclic group;X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group;ring A represents a benzene ring or a pyridine ring; andring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.
Owner:FUJIFILM RI PHARMA
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
ActiveUS20100086545A1Improves motor characteristicInhibit deteriorationAnimal cellsNervous disorderSynucleinLewy body
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Owner:RGT UNIV OF CALIFORNIA +1
Novel pyrazole derivative
It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and / or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
Owner:MOCHIDA PHARM CO LTD
Anti-ADDL antibodies and uses thereof
ActiveUS7780963B2Inhibit phosphorylationPrevent and treat diseaseNervous disorderMetabolism disorderOligomerTau phosphorylation
The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β1-42.
Owner:MERCK SHARP & DOHME LLC +1
Use of compounds having ccr antagonism
InactiveUS20050245537A1Effective preventionEffective treatmentBiocideSenses disorderAutoimmune conditionAutoimmune disease
It is intended to provide preventives / remedies for graft-versus-host disease and / or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives / remedies for graft-versus-host disease and / or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.
Owner:TAKEDA PHARMA CO LTD +1
Modified free-living microbes, vaccine compositions and methods of use thereof
ActiveUS7833775B2Reduce microbesReduce proliferationBacterial antigen ingredientsNervous disorderTumour-associated antigenGene mutation
Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and / or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and / or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and / or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Anti-Addl Antibodies and Uses Thereof
ActiveUS20080175835A1Inhibit phosphorylationPrevent and treat diseaseNervous disorderMetabolism disorderOligomerPhosphorylation
The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.
Owner:MERCK SHARP & DOHME LLC +1
Anti-ADDL monoclonal antibody and use thereof
ActiveUS7731962B2Prevent and treat diseaseNervous disorderImmunoglobulins against animals/humansOligomerAmyloid beta
Owner:MERCK SHARP & DOHME LLC
Materials and method of modulating the immune response
InactiveUS20060233750A1Enhance immune responsePrevent and treat diseasePeptide/protein ingredientsMammal material medical ingredientsDiseaseDendritic cell
Methods and materials to modulate the immune response to treat or prevent a disease, including methods of making T helper-antigen presenting cells and methods of using these cells. The invention also relates to methods of making exosome-absorbed dendritic cells and the uses of these cells to modulate the immune response to treat or prevent a disease.
Owner:UNIVERSITY OF SASKATCHEWAN
Pharmaceutical composition for preventing or treating diseases associated with beta-amyloid accumulation containing morpholin or piperazine based compounds having so3h or cooh as active ingredient
ActiveUS20110144111A1Prevent and treat diseaseOrganic active ingredientsNervous disorderMorpholineMedicine
Disclosed herein is a method for treating diseases associated with beta amyloid accumulation, including administering to a patient a therapeutically effective amount of morpholine or piperazine based compounds including a sulfuric or carboxylic acid structure represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:(wherein Z, R1 and R2 are as defined in the specification).
Owner:KOREA INST OF SCI & TECH
In vivo targeting of dendritic cells
InactiveUS20070026057A1Prevent and treat diseaseAntibacterial agentsOrganic active ingredientsWilms' tumorLiposome
The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections.
Owner:LIPOTEK PTY LTD
Cell
ActiveUS20190023761A1Prevent and treat diseasePolypeptide with localisation/targeting motifImmunoglobulin superfamilyHeterologousPhosphorylation
The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.
Owner:AUTOLUS LIMIED
Composition containing moutan root bark extract as active ingredient
InactiveUS20050084553A1High antibacterial activityEasily and simply applied to affected partsCosmetic preparationsBiocideDisinfectantCleansing Agents
The present invention relates to a composition comprising a Moutan root bark extract as an active ingredient, and particularly to a composition for the prevention and treatment of athlete's foot, osmidrosis, or acne; a composition for oral cleansing; a bactericidal / disinfectant composition; a composition for eliminating dandruff-causing pathogens and controlling odor, and a functional kitchen detergent composition. The compositions comprising the Moutan root bark extract as an active ingredient of the present invention have superior bactericidal effects against bacteria including athlete's foot-causing pathogens, skin eczema-causing pathogens and skin flora, and fungi, and they can be easily and simply applied to medicines, cosmetics, or cleansing agents.
Owner:MST
Anti FGF23 antibody and a pharmaceutical composition comprising the same
ActiveUS7883705B2Suppress actionLess side effectsMuscular disorderSkeletal disorderAntiendomysial antibodiesPharmaceutical drug
To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).
Owner:KYOWA HAKKO KIRIN CO LTD
Promoter for bicarbonate secretion in gastrointestinal tract
InactiveUS20110071075A1Prevent and treat diseaseOrganic active ingredientsBiocideChemistryAmino acid derivative
A substance is described which can prevent or treat a disease associated with the secretion of an acid. A calcium receptor activator is the active ingredient in a composition which promotes bicarbonate secretion in a gastrointestinal tract. Examples of the calcium receptor activator include γ-Glu-X-Gly, wherein X represents an amino acid or an amino acid derivative, γ-Glu-Val-Y, wherein Y represents an amino acid or an amino acid derivative, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, and γ-Glu-Cys(S-Me).
Owner:AJINOMOTO CO INC
Thienopyrimidine compounds and use thereof
The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C1-4 alkyl and (4′) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a C1-4 alkoxy-C1-4 alkyl, (3′) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4′) a C1-4 alkoxy and (5′) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
Owner:TAKEDA PHARMA CO LTD
Peptide pet food material having anti-stress action and palatability-increasing effect
InactiveUS20090028997A1Improve palatabilityRelieve pressureMilk preparationAnimal feeding stuffAnti stressAdditive ingredient
The present invention provides a safe pet food material having an anti-stress action and effect of increasing palatability. Livestock meat or fish meat is treated with a protease such as papain to obtain a pet food material with excellent thermal stability having peptides consisting of 2-10 amino acid residues as a principal active ingredient. A pet food exhibiting an anti-stress action and having high palatability is obtained by blending this material.
Owner:THE KITASATO INST
Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved
ActiveUS20090074788A1Improve the quality of lifeVital prognosisNervous disorderDigestive systemDiseaseCell adhesion
The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.
Owner:OSAKA UNIV
Pyrazole derivative
ActiveUS8980889B2Avoid hydrolysisImprove diseaseOrganic active ingredientsNervous disorderDiseaseCarboxylic acid
It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and / or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
Owner:MOCHIDA PHARM CO LTD
Purine analogs
ActiveUS20110098294A1Prevent and treat diseaseBiocidePeptide/protein ingredientsDiseaseDisease injury
The present invention provides a new patentable class of purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals.
Owner:RGT UNIV OF CALIFORNIA
Compounds useful for the treatment of metabolic disorders and synthesis of the same
InactiveUS20160046560A1Prevent and treat diseaseBiocideCarboxylic acid nitrile preparationMetabolic disorderStereochemistry
The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
Owner:NORTH CAROLINA CENTRAL UNIVERSITY +1
Compositions and methods for the treatment of pathological condition(s) related to GPR35 and/or GPR35-herg complex
InactiveUS20120022116A1Prevent and treat diseaseDesired sizeBiocideOrganic chemistryPathophysiologyHUMAN ETHER-A-GO-GO-RELATED GENE
Disclosed are compositions and methods for the prevention and / or treatment of diseases which are pathophysiologically related to GPR35, and / or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and / or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):
Owner:CORNING INC
Pyrazole derivative
It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and / or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
Owner:MOCHIDA PHARM CO LTD
Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor
ActiveUS9249153B2Inhibit overexpressionPrevent and treat diseaseCompound screeningOrganic chemistryAge related diseaseAging-associated diseases
Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression.
Owner:PUSAN NAT UNIV IND UNIV COOPERATION FOUND +1
Human-derived cell-permeable peptide bioactive peptide conjugate, and use thereof
ActiveUS20130237484A1Prevent and treat diseasePeptide/protein ingredientsAntipyreticDelivery vehicleImmunogenicity
The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof.According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.
Owner:SEOUL NAT UNIV R&DB FOUND +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com